Co-processed Excipients

Co-processed Excipients International Regulatory & Filing Guidelines

Updated: Jun 2025QTC Global Compliance TeamRegulatory reference content

Interpreting co-processed excipients definitions, process validation, toxicological safety assessment, and DMF submissions to FDA/NMPA.

Key answer

Co-processed excipients are composite materials formed by physically combining two or more monograph excipients (e.g., spray drying, co-crystallization) to yield improved performance (e.g., direct compression, rapid dissolution). Agencies do not treat them as simple physical mixtures; dossiers must justify process consistency, structural characterization, and provide toxicological safety assessments.

Technical Focus in Co-processed Excipient Dossiers

Because co-processing combines multiple ingredients physically, agencies review batch homogeneity to prevent dose variations in tablet formulation.

  • No chemical modification: XRD and FTIR scans confirming no covalent bond formation between components
  • Composition consistency: proving ingredient ratios remain homogenous throughout spray drying or crystallization
  • Unified specifications: establishing single spec profiles, including particle size distributions, bulk density, and LOD

FAQ

Is a dry blend considered a co-processed excipient?+

No. A dry blend is just a simple mixture; its components maintain individual identity. Co-processed excipients require specific physical processing (e.g. co-drying) changing particle geometry, and the ingredients cannot be easily separated physically.

Next steps

If this topic applies to your product, facility, or supply chain requirement, start by confirming the target market, customer-required standard, existing documents, audit history, and expected timeline.